AI Article Synopsis
Article Abstract
Solute-free water clearance increased by 186% in water loaded rats treated with glucagon-like peptide 1 compared to untreated group. The effect of glucagon-like peptide 1 was reproduced in experiments with its synthetic analogue exenatide. Serum osmolality in water loaded rats treated with exenatide was closer to normal level on 30, 45, 60 min of experiment compared to the untreated group and reached the control value in 60 min. Administration of glucagon-like peptide 1 receptor antagonist to water loaded rats delayed (5 ml per 100 g bw) or prevented (2 ml per 100 g bw) increase in solute-free water clearance. The obtained data suggest the involvement of glucagon-like peptide 1 in osmotic homeostasis and indicate the unique physiologic role of incretins in regulation of water balance.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Immune Dysregulation in Obesity.
Annu Rev Pathol
January 2025
Diabetes Center and Department of Laboratory Medicine, University of California, San Francisco, California, USA;
The immune system plays fundamental roles in maintaining physiological homeostasis. With the increasing prevalence of obesity-a state characterized by chronic inflammation and systemic dyshomeostasis-there is growing scientific and clinical interest in understanding how obesity reshapes immune function. In this review, we propose that obesity is not merely an altered metabolic state but also a fundamentally altered immunological state.
View Article and Find Full Text PDFExploring the hair loss risk in glucagon-like peptide-1 agonists: Emerging concerns and clinical implications.
J Eur Acad Dermatol Venereol
February 2025
Department of Medicine Sciences, University of New England College of Osteopathic Medicine, Biddeford, Maine, USA.
Is Weight Loss the Main Driver for A1C Improvement by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists? A 2.5-Year Analysis in Real-World Clinical Practice.
J Diabetes
January 2025
Joslin Diabetes Center, Affiliated With Harvard Medical School, Boston, Massachusetts, USA.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are established treatment options for type 2 diabetes (T2D). In addition to their glycemic benefit, GLP-1 RAs also induce weight loss by suppressing appetite via hypothalamic pathways. However, it remains unclear whether weight reduction is the primary driver of glycemic improvement.
View Article and Find Full Text PDFDiscovery of 1,4-Disubstituted Cyclohexene Analogues as Selective GPR119 Agonists for the Treatment of Type 2 Diabetes.
J Med Chem
January 2025
School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
GPR119 has emerged as a promising target for treating type 2 diabetes and associated obesity, as its stimulation induces the secretion of glucagon-like peptide-1 and glucose-dependent insulinotropic peptide in the intestinal tract as well as the glucose-dependent release of insulin in pancreatic β-cells. We describe the design and synthesis of novel GPR119 agonists containing a 1,4-disubstituted cyclohexene scaffold. Compound displayed nanomolar potency (EC = 3.
View Article and Find Full Text PDFThe Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required.
Metabolites
January 2025
Department of Geriatric Medicine, Rotherham General Hospital, Moorgate Road, Rotherham S60 2UD, UK.
Frailty is an increasingly recognised complication of diabetes in older people and should be taken into consideration in management plans, including the use of the new therapies of sodium glucose cotransporter-2 (SGLT-2) inhibitors and glucagon like peptide-1 receptor agonists (GLP-1RA). The frailty syndrome appears to span across a spectrum, from a sarcopenic obese phenotype at one end, characterised by obesity, insulin resistance, and prevalent cardiovascular risk factors, to an anorexic malnourished phenotype at the other end, characterised by significant weight loss, reduced insulin resistance, and less prevalent cardiovascular risk factors. Therefore, the use of the new therapies may not be suitable for every frail older individual with diabetes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!